Antibody assesement for COVID-19 prevalence two months after outbreak in the hot spot Region of Tirschenreuth / Bavaria

Antibody assesement for COVID-19 prevalence two months after outbreak in the hot spot Region of Tirschenreuth / Bavaria - AK-TIR-COVID-19

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00021813

Enrollment

2500

Registered

2020-06-29

Start date

2020-06-29

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1, suspicion of COVID-19 J12.8 B97.2

Interventions

Group 1: participant of Kliniken Nordoberpfalz AG: blood sampling to evidence from antibody of SARS-CoV-2 (COVID-19) in blood Serum (once) by clinic participant of the "hotspot"region Tirschenreuth Gr

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Employee of Kliniken Nordoberpfalz AG or Witron Group. participants >= 18 years. In writing, signed and dated Informed consent after verbal Information.

Exclusion criteria

Exclusion criteria: <18 years. Subject has not given consent for the clinical Trial.

Design outcomes

Primary

Measure	Time frame
Seroprevalence of antibodies vs COVID-19 in medical and non-medical working population.	—

Secondary

Measure	Time frame
Seroprevalence of antibodies vs COVID-19 in different departements of hospital Workers. COVID-vs Non-COVID ward. Doctors vs nurses.	—

Countries

Germany

Contacts

Public ContactThomas Finkenzeller

Kliniken Nordoberpfalz AG

thomas.finkenzeller@kliniken-nordoberpfalz.ag+49 961 303 12887

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026